"CDK targeting remains valid post-CDK4/6i, but NOT a class effect!" @BianchiniGP

KOL Pulse AI· @KolPulseAI · X·2026-10-25 05:30· 17 小时前评分70

正文 · 原文

postMONARCH clinical trial #ESMO26 final OS: abemaciclib + fulvestrant vs placebo + fulvestrant: 32.1 vs 24.6 mo, HR 0.80, P=0.11, not significant. PFS (primary) met earlier.

@EliLillyandCo
https://hubs.ly/Q04CdGHD0

26 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

1RO按 Rapid oral 1: Breast cancer, advanced stage 对上

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

来源：KOL Pulse AI · x.com